WADA Considers Adding Semaglutide to Prohibited List Ahead of LA28 Olympics

The World Anti-Doping Agency (WADA) is actively evaluating whether to add semaglutide—the active ingredient in blockbuster weight-loss medications like Ozempic and Wegovy—to its Prohibited List ahead of the 2028 Los Angeles Olympics. The global regulatory body placed glucagon-like peptide-1 (GLP-1) receptor agonists on its official Monitoring Program in 2024 to track potential abuse across elite sports. Officials are now systematically gathering data from in-competition and out-of-competition testing to determine if the widespread use of these drugs crosses the line from legitimate medical treatment to illicit performance enhancement. With the Los Angeles Games on the horizon, the decision will fundamentally shape how endurance and weight-class sports govern metabolic interventions.[1][3]

The current debate within the anti-doping community centers on the profound metabolic shifts these medications induce. Originally developed to manage Type 2 diabetes and clinical obesity, GLP-1 agonists work by mimicking a hormone that slows gastric emptying and signals fullness to the brain. This mechanism leads to significant weight loss without the traditional physiological stress and mental fatigue of severe calorie restriction. In disciplines where a high power-to-weight ratio is the ultimate currency—such as professional cycling, distance running, and triathlon—the ability to shed excess mass effortlessly presents a tantalizing and potentially game-changing advantage for competitors looking to optimize their biomechanics.[1][2]

Under the established framework of the World Anti-Doping Code, a substance can be formally banned if it meets at least two of three strict criteria: it has the potential to enhance sport performance, it represents an actual or potential health risk to the athlete, or it violates the fundamental spirit of sport. WADA's senior director of medicine and science, Dr. Olivier Rabin, has publicly noted that the traditional paradigm of weight control in athletics is rapidly shifting due to these pharmaceuticals. The agency is currently investigating whether the effortless weight management provided by GLP-1s provides an unfair physiological edge, particularly in endurance events where carrying less weight directly translates to faster times and reduced energy expenditure.[1][3]

Endurance sports are already grappling with the cultural and competitive implications of this pharmacological shift. In professional cycling and track and field, where athletes have historically relied on grueling, highly regimented dietary protocols to reach their optimal race weight, the prospect of a pharmaceutical shortcut has raised significant alarms. A recent comprehensive survey of sports physicians working with highly trained competitors revealed that one in ten were already aware of athletes using weight-loss drugs without any underlying medical necessity. Furthermore, nearly half of the surveyed medical professionals advocated for WADA to implement a strict ban, citing concerns over fairness and the long-term physical toll on the athletes.[2]

Despite the allure of rapid weight loss, sports medical professionals caution that the perceived performance benefits may actually be a mirage accompanied by severe physiological drawbacks. While shedding body fat can theoretically improve aerobic capacity metrics like VO2 max, clinical data shows that GLP-1 medications frequently cause a concurrent loss of lean muscle mass. For elite athletes, maintaining muscle density is critical for generating explosive power, sustaining endurance, and preventing structural injuries. Furthermore, the profound appetite suppression inherent to the drugs can easily lead to low energy availability, severely impairing an athlete's ability to fuel intense training sessions and recover adequately between demanding competitive events.[2]

The gastrointestinal side effects associated with semaglutide present another significant hurdle for elite competitors attempting to use the drug for a competitive edge. The delayed gastric emptying that makes the medication so effective for weight loss can simultaneously cause severe nausea, bloating, and vomiting. These symptoms are highly disruptive and can become debilitating during high-intensity workouts or grueling endurance races. Sports dietitians consistently warn that the inability to absorb essential carbohydrates and hydration efficiently during competition could ultimately degrade an athlete's performance rather than enhance it, making the off-label use of GLP-1s a highly risky gamble for those seeking a spot on the Olympic podium.[2]

The primary regulatory challenge for WADA moving forward is distinguishing between the legitimate therapeutic use of these medications and performance-driven abuse. If semaglutide and other GLP-1 agonists are ultimately added to the Prohibited List, athletes who genuinely require the medication for diagnosed metabolic conditions or diabetes would not be entirely shut out of competition. Instead, they would need to apply for a Therapeutic Use Exemption (TUE) through their national anti-doping organizations. This rigorous medical review process would allow them to continue their prescribed treatment without facing competitive sanctions, thereby maintaining a delicate balance between ensuring fair play and protecting athlete health.[1][3]

As the 2028 Los Angeles Olympics approach, the global sports community remains deeply divided on how to handle the GLP-1 revolution. While some advocates argue that the drugs simply level the playing field for athletes struggling with genetic metabolic inefficiencies, critics view them as a dangerous shortcut that promotes toxic body image standards and exacerbates the risk of eating disorders within elite sports. WADA's ongoing data collection and urine analysis over the next two years will be critical in shaping the future of anti-doping policy, determining whether metabolic optimization through pharmaceuticals becomes the new normal or a banned practice in the pursuit of clean sport.[1][2][3]